Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548205 · ClinicalTrials.gov registry record · NA
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
A NA study of Diabetes, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05548205: Recruiting NA study of Diabetes, sponsored by NYU Langone Health.
NCT05548205 is a NA study of Diabetes that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 150 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05548205, a NA study of Diabetes, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.
Primary Outcome
Assessed via CGM or BGM.
Conditions Studied
Interventions
- DEVICE Continuous Glucose Monitor
- DEVICE Blood Glucose Monitor
Study Locations (1)
New York
- NYU Langone Hospital - Long Island - Mineola
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2027-04-30 |
| Phase | NA |
What NCT05548205 shows while recruiting
NCT05548205 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Continuous Glucose Monitor is the first listed.
NCT05548205 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05548205 about?
NCT05548205 is a clinical study titled "Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge". The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for ...
What is the current status of trial NCT05548205?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-12-16. Estimated completion is 2027-04-30.
What conditions does trial NCT05548205 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT05548205?
The interventions under investigation include: Continuous Glucose Monitor (DEVICE), Blood Glucose Monitor (DEVICE).
Who is sponsoring clinical trial NCT05548205?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05548205 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05548205's enrollment target sits among peer trials
150 165th of 338 higher than 168 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
-
Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitoring
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI